A phase 1b/2 study of JK06, a 5T4-targeted antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer.
Omar Saavedra(Hospital Quirónsalud Barcelona), Nuria Kotecki(Centre Oscar Lambret), B. Dekeyser(Antwerp University Hospital), Vladimir Galvao(Hebron University), Naimish Pandya(Integrated BioTherapeutics (United States)), Jonathan P. McNally(Integrated BioTherapeutics (United States)), Lionel D’Hondt(CHU Dinant Godinne UCL Namur), Shalabh Singhal(Integrated BioTherapeutics (United States)), A. Drumheller(Integrated BioTherapeutics (United States)), V. Boni(Hospital Universitario Quirónsalud Madrid), Samuel Murphy(Integrated BioTherapeutics (United States)), Maria de Miguel, Brant Delafontaine, Fabricio Racca(Hospital Universitario Dexeus), Sylvie Rottey(Ghent University Hospital), Emiliano Calvo, Valentina Gambardella(Universitat de València), Hans Prenen(Universitair Ziekenhuis Leuven), Jennifer Lindelien(Integrated BioTherapeutics (United States)), Jijun Dong(Integrated BioTherapeutics (United States))
Cited by 0
Related Papers
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
|JAMA Oncology|2018|315
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
|Nature Medicine|2025|104
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93